|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:ATCCode
|
L01XC12
|
|
gptkbp:blackBoxWarning
|
gptkb:progressive_multifocal_leukoencephalopathy
|
|
gptkbp:CASNumber
|
914088-09-8
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Seattle_Genetics
|
|
gptkbp:form
|
lyophilized powder for solution for infusion
|
|
gptkbp:genericName
|
gptkb:brentuximab_vedotin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adcetris
|
|
gptkbp:indication
|
Hodgkin lymphoma
systemic anaplastic large cell lymphoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Seagen_Inc.
|
|
gptkbp:mechanismOfAction
|
antibody-drug conjugate targeting CD30
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
none
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
fatigue
peripheral neuropathy
neutropenia
|
|
gptkbp:target
|
gptkb:CD30
|
|
gptkbp:type
|
monoclonal antibody-drug conjugate
|
|
gptkbp:UNII
|
2K8Q726O95
|
|
gptkbp:bfsParent
|
gptkb:Seagen
|
|
gptkbp:bfsLayer
|
5
|